Management of locally advanced prostate cancer
T he management of prostate cancer involves the consideration of a number of clinical, biological and patient factors in order to determine the most appropriate treatment. These include the clinical stage of the tumour, the presence or absence of high-risk features, and individual patient factors such as comorbidities and performance status. There is then careful discussion between the patient and the multidisciplinary team regarding treatment options and their potential risks and benefits ( Figure 1 ).
Clinical stage is defined using the American Joint Committee on Cancer staging system. 1 Locally advanced prostate cancer includes T3 and T4 disease (where tumour extends beyond the prostate capsule and may invade
The management of locally advanced or high-risk prostate cancer is challenginginvolving the patient and multidisciplinary team in decision-making is essential so that treatment is tailored to the individual. Progression from locally advanced to metastatic disease and the development of metastatic pain occurred more rapidly in patients who received deferred hormone therapy. In addition, complications from metastatic disease, such as pathological fractures, spinal cord compression and ureteric obstruction, were twice as common in deferred patients. This study suggested that early hormone therapy reduces disease progression and the complications due to progression. 
RADICAL PROSTATECTOMY

RADIOTHERAPY
Radiotherapy entails targeted delivery of high-energy X-rays, which cause doublestrand DNA breaks and subsequent tumour cell death. Individualised radiotherapy plans deliver a high dose to the tumour volume while minimising irradiation of normal tissues such as the bladder and rectum.
Technological advances in radiotherapy planning have enabled a shift from twodimensional to three-dimensional CT-based conformal planning, and more recently sophisticated dose distributions can be achieved with intensity-modulated radiotherapy. More precise delivery of radiotherapy to the target volume has allowed dose escalation to the tumour while ensuring normal structures are within tolerance levels. This has been shown to improve local tumour control. A UK study found an improved five-year biochemical progression-free survival rate of 71 per cent when treating to an increased radiotherapy dose of 74Gy, compared with 60 per cent in men randomised to receive 64Gy. 7 This dose of 74Gy has been adopted as standard UK practice. Radiotherapy is currently delivered in small daily fractions, Monday to Friday, continuously for 7.5 weeks. Early side-effects include cystitis, faecal frequency and urgency, proctitis and rectal bleeding. Late complications occurring three months or later after treatment include erectile dysfunction, bleeding, proctitis and diarrhoea.
The dose may be further escalated with high-dose-rate brachytherapy, which entails insertion of a radioactive iridium source temporarily into the prostate gland. This may be used in combination with external beam radiotherapy.
RADIOTHERAPY WITH CONCOMITANT HORMONE THERAPY
Patients with locally advanced or high-risk disease carry a risk of micrometastases, which needs to be addressed for optimal treatment. Neoadjuvant hormone therapy commenced before radiotherapy reduces tumour bulk and prostate volume, reducing the size of the required radiotherapy fields and potential toxicity to the surrounding normal tissues. Hormone therapy may also sensitise tumour cells to the radiotherapy treatment.
An early study, which randomised patients between radical radiotherapy with or without four months of neoadjuvant hormone therapy (goserelin and flutamide), has demonstrated significant improvements with combined treatments. The 10-year disease-specific mortality was significantly lower in the hormone-treated group (23 versus 36 per cent), as was distant metastasis (35 versus 47 per cent), disease-free survival (11 versus 3 per cent) and biochemical failure (65 versus 80 per cent). 8 Adjuvant hormone treatment immediately after radical radiotherapy has shown a significant improvement in overall survival, progression-free survival, local control and risk of distant metastases in several large, international, phase 3 randomised trials.
In one such study, Bolla and colleagues randomised high-risk patients between
The benefit of the addition of radiotherapy to hormonal treatment has also been investigated radiotherapy alone with hormones on progression and radiotherapy with three years of adjuvant goserelin. 9 At five-year follow-up, overall survival in those treated with immediate hormones was significantly superior (78 versus 62 per cent), as was disease-free survival (74 versus 40 per cent; Figure 2 ). Further benefit in overall survival was seen at 10 years (39.8 versus 58.1 per cent). 10 There were similar very significant improvements in progression-free survival and clinical or PSA relapse.
The large, Early Prostate Cancer study included a subgroup of patients with locally advanced disease treated with radiotherapy, who were randomised between additional adjuvant bicalutamide 150mg once daily and placebo. 11 The addition of bicalutamide significantly improved overall survival (hazard ratio 0.65) and reduced the risk of prostate-cancer-related death compared with placebo.
Given this demonstrated efficacy of hormones, the benefit of the addition of radiotherapy to hormonal treatment has also been investigated. 12 Patients treated with hormones alone were found to have a 10-year prostate-cancer-specific mortality of 23.9 per cent compared with 11.9 per cent in those who received hormones plus radiotherapy. There was an acceptable risk of side-effects in the radiotherapy group.
Although trials of radiotherapy and hormone therapy have used different hormone agents, varying the timing and duration, there is strong evidence for benefits in overall and disease-free survival when radiotherapy is used in combination with hormonal treatment. This combined modality approach is therefore standard to achieve optimal outcomes in locally advanced and high-risk prostate cancer.
CONCLUSION
The management of locally advanced or high-risk prostate cancer is challenging. Optimal patient care is dependent upon discussion and collaboration between radiologists, pathologists, oncologists, urologists and specialist nurses to recommend the most appropriate options for an individual patient. 
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